Cargando…

Jemperli (Dostarlimab-gxly): An unprecedented cancer trial

Detalles Bibliográficos
Autores principales:	Ali, Eman, Ellahi, Aayat, Adil, Mariam, Shaikh, Asim, Huda, Zunera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289402/ https://www.ncbi.nlm.nih.gov/pubmed/35860105 http://dx.doi.org/10.1016/j.amsu.2022.104047

Ejemplares similares

Neurological manifestations of COVID-19: A perspective from Pakistani medical students
por: Adil, Mariam, et al.
Publicado: (2022)

Stigmatization of schizophrenic individuals and its correlation to the fear of violent offence. Should we be concerned?
por: Adil, Mariam, et al.
Publicado: (2022)

Effectiveness of endovascular repair versus open surgery for the treatment of thoracoabdominal aneurysm: A systematic review and meta analysis
por: Ellahi, Aayat, et al.
Publicado: (2022)

Dostarlimab: A breakthrough in the field of oncology
por: Hussain, Hassan ul, et al.
Publicado: (2022)

Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
por: Siddiqui, Tasmiyah, et al.
Publicado: (2022)

Vitamin B6: A new approach to lowering anxiety, and depression?
por: Durrani, Duaa, et al.
Publicado: (2022)

Dostarlimab, a boon or a healthcare burden- too early to acertain!
por: Fatima, Nabeela, et al.
Publicado: (2022)

Influenza vaccination and dementia risk; an unanticipated benefit?
por: Ali, Eman, et al.
Publicado: (2022)

Violence against doctors at government tertiary care hospitals in Pakistan: Someone’s life over your own?
por: Razzaq, Nayab, et al.
Publicado: (2022)

Monkeypox virus: A spreading threat for Pakistan?
por: Najeeb, Hala, et al.
Publicado: (2022)

Dostarlimab: A Review
por: Costa, Bárbara, et al.
Publicado: (2022)

An Integrated Analysis of Dostarlimab Immunogenicity
por: Lu, Sharon, et al.
Publicado: (2021)

Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata
por: Ali, Eman, et al.
Publicado: (2022)

Post-COVID-19 vaccine-associated menstrual cycle changes: A multifaceted problem for Pakistan
por: Liaquat, Ayesha, et al.
Publicado: (2022)

Dostarlimab: The miracle drug for the treatment of colorectal cancer
por: Shuvo, Pollob Ahmed, et al.
Publicado: (2022)

Monkeypox and fecal microbiota for transplantation(FMT): An unprecedented risk?
por: Owais, Rabia, et al.
Publicado: (2022)

Dementia and non-alcoholic fatty liver disease – An unprecedented relationship
por: Latif, Fakhar, et al.
Publicado: (2022)

Dostarlimab/tozinameran: Various toxicities: case report
Publicado: (2022)

Reframing the banning of flavored tobacco in unprecedented times- an example from California’s Senate bill 793
por: Tang Ker, Jasmine, et al.
Publicado: (2022)

Diseases caused by floods with a spotlight on the present situation of unprecedented floods in Pakistan: a short communication
por: Naeem, Aroma, et al.
Publicado: (2023)

Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
por: Singh, Vanshikha, et al.
Publicado: (2022)

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

Unprecedented plastic-made personal protective equipment (PPE) debris in river outlets into Jakarta Bay during COVID-19 pandemic
por: Cordova, Muhammad Reza, et al.
Publicado: (2021)

Self-Assembled Capsules of Unprecedented Shapes**
por: Tiefenbacher, Konrad, et al.
Publicado: (2011)

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
por: Mathews, Cara, et al.
Publicado: (2022)

Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series
por: Marzoughi, Sina, et al.
Publicado: (2021)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
por: Alkholifi, Faisal K., et al.
Publicado: (2022)

Correction to: An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
Publicado: (2022)

Lugdunomycin, an Angucycline‐Derived Molecule with Unprecedented Chemical Architecture
por: Wu, Changsheng, et al.
Publicado: (2019)

Synthesis of Unprecedented 4d/4f‐Polypnictogens
por: Reinfandt, Niklas, et al.
Publicado: (2021)

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
por: Bartoletti, Michele, et al.
Publicado: (2022)

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
por: You, Maojin, et al.
Publicado: (2023)

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
por: Yap, Timothy A, et al.
Publicado: (2022)

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
por: André, Thierry, et al.
Publicado: (2023)

Facteurs prédictifs de la réponse à la CERA chez les hémodialysés chroniques naïfs de traitement par agent stimulant l’érythropoïèse
por: Ezziani, Mariam, et al.
Publicado: (2015)

(18)F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab
por: Seban, Romain-David, et al.
Publicado: (2021)

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
por: Oaknin, Ana, et al.
Publicado: (2023)

Unprecedented
Publicado: (1898)

Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
por: Kristeleit, Rebecca, et al.
Publicado: (2022)

Chemical Profile and Biological Activity of Casimiroa Edulis Non-Edible Fruit`s Parts
por: Elkady, Wafaa Mostafa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n0eg9vmqn5brr4fon8cp9v475b